Venture Life Group – new structure expected to pay off with nearly six times profit this year
Mark Watson-Mitchell - 25.09.2026
Catching companies when major changes are underway can be very speculative, however there may well be a good chance of capital gains for investors taking a view on the Venture Life Group (LON:VLG) – especially ahead of its Final Results next Tuesday, 29th September.
Capitalised at just £81m, after an early May dip to only 54p. the group’s shares, now 67.50p, are edging towards their year’s High of 72p - it could be just the right time to jump aboard.
The Business
Based in Bracknell, the Venture Life Group is a consumer self-care company.
The Company is focused on product development and commercialisation within the global consumer healthcare sector.
Its product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, the Health & Her/Him product ranges supporting the hormonal lifecycle, FemiClear products addressing a range of common gynaecological conditions, plus the Curoxen brand providing infection prevention solutions for wounds and mouth sores.
The products, which are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples and are sold in over 90 countries worldwide.
In the UK and in The Netherlands, its products are supplied direct by the Company to retailers, while elsewhere they are supplied by its international distribution partners.
Latest Update
On Tuesday, 30th June, the Venture Life Group reported revenues of £50.0m for the seventeen-month period to end-May, a 30.9% increase from the prior period, with proforma revenue growth of 16.0% driven by volume.
The company expects Adjusted EBITDA to be in line with market expectations.
Power Brands, representing 91.2% of revenue in the previous five months, grew 20.7% to £13.4m, benefiting from increased marketing investment and successful international partner relationships.
Following a £17.5m advance for recent acquisitions, Net Cash stood at approximately £12.0m as at end-May.
The outlook is positive, with continued investment in Power Brands and exploration of further earnings-enhancing M&A opportunities.
Management Comment
Jerry Randall, CEO, commented:
"In delivering these excellent results, the Group has achieved robust double-digit growth and increased market penetration for its Power Brands.
While some growth reflects customer price increases to offset supply-side inflation, it is substantially volume driven.
The team has worked tirelessly to increase distribution and rate of sale, while delivering best-in-class innovation through new product launches, supported by our enhanced innovation function.
Our strategy to increase investment behind existing brands is clearly gaining traction, which is essential in a challenging consumer environment.
Through this investment we are building strong underlying growth, enhancing our market position and increasing brand awareness, which is key to the long-term, sustainable business the Board aspires to deliver.
This validation of our strategy leads us to further increase investment in the growth and development of our Power Brands, including the newly acquired FemiClear and CUROXEN brands.
I am delighted with this acquisition and the first-class sales, marketing and operational team, which gives us our first footprint in the US.
FemiClear is the clear no.2 in the US Femcare market, delivering strong revenue growth in 2026 and into 2027.
The US team has built excellent relationships with key retailers, with Femiclear present and growing in Walmart, Walgreens, CVS and Target, among others.
This brand and team will be a bridgehead into the US for other VLG brands, both present and future, in a significant and well-priced consumer healthcare market.
It is important to bed in and invest behind newly acquired brands to maximise value creation, and we intend to do this in the US.
We see significant headroom in the total addressable markets for our Power Brands, even as consumer spend remains under pressure and competition for each consumer pound intensifies.
VLG is well positioned in exciting growth categories, with true omnichannel reach in its main UK and US markets.
Our Power Brands have strong market positions that support pricing power, alongside a clear roadmap for integrated digital capabilities that are powering the business towards an exciting future."
The Equity
There are some 119.87m shares in issue.
Larger holders include Slater Investments Ltd. (14.98%), BGF Investment Management Ltd. (9.64%), Close Brothers Asset Management (Guernsey) Ltd. (8.00%), Hargreaves Lansdown Asset Management Ltd. (7.61%), Corient Investment Management Ltd. (7.01%), TrinityBridge Ltd. (6.43%), River Global Investors LLP (5.75%), Chelverton Asset Management Ltd. (3.63%), Hargreaves Lansdown Fund Managers Ltd. (1.51%), and Harwood Capital LLP (1.06%).
Broker Views
Analysts Chris Donnellen and Adam McCarter, at Cavendish Capital Markets, rate the group’s shares as a Buy, with a Target Price of 150p.
Their estimates for extended trading period to end-May 2026 are for revenues of £50.4m (2024 year £26.6m), adjusted pre-tax profits £1.1m (£1.6m), with 4.1p per share of earnings.
However, for the current year to end-May 2027, the analysts look for £54.7m of sales but with a 563% increase in profits to £6.2m, lifting earnings up to 6.9p (4.1p) per share.
For 2028 they estimate £59.7m sales, £7.7m profits and 8.2p earnings per share.
The analysts concluded by stating that:
“Venture Life’s new structure sets a strong foundation for future organic and M&A driven revenue growth with margin expansion.
The company has focused its brands on healthy longevity and will provide increased investment support to achieve market-leading positions, while enhancing growth through M&A, with both strategies supported by a strong balance sheet.
With the shares trading on c1x forward sales, we believe the Venture Life investment case remains attractive.”
My View
The major change is underway in this trading year and, judging by analyst predictions, it is rapidly paying off, with profits expected to rise nearly six-fold.
The coming year looks for a useful advance too, which must certainly please and appeal to investors - the shares, now 67.50p, could easily top the 100p level within the next year or so.
(Profile 28.07.25 @ 58.50p set a Target Price of 73p)
Comments